TY - JOUR
T1 - Assessment of the Impact of Subcutaneous Catheter Change on Glucose Control in Patients with Type 1 Diabetes Treated by Insulin Pump in Open- and Closed-Loop Modes
AU - Julla, Jean Baptiste
AU - Jacquemier, Pauline
AU - Bonnemaison, Elisabeth
AU - Fagherazzi, Guy
AU - Hanaire, Hélène
AU - Schaepelynck, Pauline Bellicar
AU - Mihaileanu, Mihaela
AU - Renard, Eric
AU - Reznik, Yves
AU - Riveline, Jean Pierre
N1 - Publisher Copyright:
ª Mary Ann Liebert, Inc.
PY - 2024/7
Y1 - 2024/7
N2 - Introduction: Most continuous subcutaneous insulin infusion (CSII) catheters (KT) are changed every 3 days. This study aims at evaluating whether KT changes impact glucose control while under open-loop (OL) or automated insulin delivery (AID) modes. Methods: We included patients with type 1 diabetes who used Tandem t:slim x2 insulin pump and Dexcom G6 glucose sensor for 20 days in OL, then as AID. CSII and sensor glucose data in OL and for the past 20 days of 3-month AID were retrospectively analyzed. The percentage of time spent with sensor glucose above 180 mg/dL (%TAR180) was compared between the calendar day of KT change (D0), the next day (D1), and 2 days later (D2). Values were adjusted for age, gender, body mass index (BMI), hemoglobin A1c (HbA1c) at inclusion, and %TAR180 for the 2 h before KT change. Results: A total of 1636 KT changes were analyzed in 134 patients: 72 women (54%), age: 35.6 – 15.7 years, BMI: 25.2 – 4.7 kg/m2, and HbA1c: 7.5 – 0.8%. %TAR180 in the 2 h before the KT change was 51.3 – 37.0% in OL and 33.2 – 30.0% in AID mode. In OL, significant absolute increases of %TAR180 at D0 versus D1 (+6.9%; P < 0.0001) or versus D2 (+6.8%; P < 0.0001) were observed. In AID, significant absolute increases of %TA180R at D0 versus D1 (+4.8%; P < 0.0001) or versus D2 (+4.2%; P < 0.0001) were also observed. Conclusion: This study shows an increase in time spent in hyperglycemia on the day of the KT change both in OL and AID modes. This additional information should be taken into account to improve current AID algorithms. ClinicalTrials.gov: NCT 04939766.
AB - Introduction: Most continuous subcutaneous insulin infusion (CSII) catheters (KT) are changed every 3 days. This study aims at evaluating whether KT changes impact glucose control while under open-loop (OL) or automated insulin delivery (AID) modes. Methods: We included patients with type 1 diabetes who used Tandem t:slim x2 insulin pump and Dexcom G6 glucose sensor for 20 days in OL, then as AID. CSII and sensor glucose data in OL and for the past 20 days of 3-month AID were retrospectively analyzed. The percentage of time spent with sensor glucose above 180 mg/dL (%TAR180) was compared between the calendar day of KT change (D0), the next day (D1), and 2 days later (D2). Values were adjusted for age, gender, body mass index (BMI), hemoglobin A1c (HbA1c) at inclusion, and %TAR180 for the 2 h before KT change. Results: A total of 1636 KT changes were analyzed in 134 patients: 72 women (54%), age: 35.6 – 15.7 years, BMI: 25.2 – 4.7 kg/m2, and HbA1c: 7.5 – 0.8%. %TAR180 in the 2 h before the KT change was 51.3 – 37.0% in OL and 33.2 – 30.0% in AID mode. In OL, significant absolute increases of %TAR180 at D0 versus D1 (+6.9%; P < 0.0001) or versus D2 (+6.8%; P < 0.0001) were observed. In AID, significant absolute increases of %TA180R at D0 versus D1 (+4.8%; P < 0.0001) or versus D2 (+4.2%; P < 0.0001) were also observed. Conclusion: This study shows an increase in time spent in hyperglycemia on the day of the KT change both in OL and AID modes. This additional information should be taken into account to improve current AID algorithms. ClinicalTrials.gov: NCT 04939766.
KW - Automated insulin delivery
KW - Catheter changes
KW - CSII
KW - Type 1 diabetes
UR - http://www.scopus.com/inward/record.url?scp=85187662540&partnerID=8YFLogxK
UR - https://pubmed.ncbi.nlm.nih.gov/38350126
U2 - 10.1089/dia.2023.0568
DO - 10.1089/dia.2023.0568
M3 - Article
C2 - 38350126
AN - SCOPUS:85187662540
SN - 1520-9156
VL - 26
SP - 442
EP - 448
JO - Diabetes Technology and Therapeutics
JF - Diabetes Technology and Therapeutics
IS - 7
ER -